Bladder EpiCheck clinical utility to predict BCG response in non-muscle-invasive bladder cancer

被引：0

作者：

Roldan, Fiorella L. ^{[1
,2
]}

Ingelmo-Torres, Mercedes ^{[1
,2
]}

Mercader, Claudia ^{[1
,2
]}

Figueras, Marcel ^{[1
,2
]}

Padulles, Bernat ^{[1
,2
]}

Duran, Maria Angeles ^{[1
]}

Carrasco, Josep L. ^{[3
]}

Ribal, Maria Jose ^{[1
,2
]}

Franco, Agustin ^{[1
]}

Izquierdo, Laura ^{[1
,2
]}

Alcaraz, Antonio ^{[1
,2
]}

Mengual, Lourdes ^{[1
,2
,4
]}

机构：

[1] Hosp Clin Barcelona, Lab & Serv Urol, Barcelona, Spain

[2] Fundacio Recerca Clin Barcelona Inst Invest Biomed, Genet & Tumors Urol, Barcelona, Spain

[3] Univ Barcelona UB, Dept Fonaments Clin, Fac Med & Ciencies Salut, Unitat Bioestadist, Barcelona, Spain

[4] Univ Barcelona UB, Dept Biomed, Fac Med & Ciencies Salut, Unitat Genet, Barcelona, Spain

来源：

BJU INTERNATIONAL | 2025年

关键词：

Bacillus Calmette-Guerin (BCG); BCG response; bladder cancer; bladder EpiCheck; methylation biomarkers; predictive biomarkers; urine; IN-SITU HYBRIDIZATION; SURVEILLANCE; THERAPY; TUMORS; RISK;

D O I：

10.1111/bju.16697

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Objective To evaluate the performance of Bladder Epicheck (R) (BE; Nucleix Ltd., Rehovot, Israel) in predicting tumour recurrence and bacillus Calmette-Gu & eacute;rin (BCG) failure during the first year after induction treatment. Patients and methods Prospective study including 65 patients with non-muscle-invasive bladder cancer treated with BCG between 2018 and 2021. Urine samples analysed with BE were collected before and after BCG induction. Logistic binary regression was used to assess the association between clinical and pathological variables and BE results with tumour recurrence and BCG failure during the first year after induction treatment. Results During follow-up, 16 (24.6%) patients experienced a bladder cancer event, 11 (68.8%) of which were BCG failure (high-grade recurrence) and five (31.2%) were low-grade recurrences. The median (range) time to overall recurrence was 7.3 (3.8-17.4) months. A significant association was found between the risk of tumour recurrence/BCG failure and post-BCG cystoscopy (odds ratio [OR] 10.0; P < 0.001 and OR 13.1; P < 0.001, respectively), post-BCG BE result (OR 16.9; P < 0.001 and OR 33.1; P < 0.001, respectively) and pre/post-BCG EpiScore value variation (OR 14.4; P = 0.001 and OR 7.1; P = 0.018, respectively). A nomogram including these three variables outperformed the Club Urologico Espanol de Tratamiento Oncologico (CUETO) risk tables to predict any bladder cancer event after BCG induction (area under the curve 95.1% vs 67.1%). Result validation in a larger and independent series is needed. Conclusions The BE post-BCG status and variations in EpiScore values can help us identify patients at higher risk of any bladder cancer event and BCG failure promptly. These data can have an impact on disease management.

引用

页数：8

共 22 条

[1]

Sylvester R.J., Van der Meijden A.P.M., Lamm D.L., Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials, J Urol, 168, pp. 1964-1970, (2002)

[2]

Fernandez-Gomez J., Madero R., Solsona E., Et al., Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model, J Urol, 182, pp. 2195-2203, (2009)

[3]

Witjes J.A., Management of BCG failures in superficial bladder cancer: a review, Eur Urol, 49, pp. 790-797, (2006)

[4]

Huguet J., Crego M., Sabate S., Salvador J., Palou J., Villavicencio H., Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor, Eur Urol, 48, pp. 53-59, (2005)

[5]

Schrier B.P., Hollander M.P., Van Rhijn B.W.G., Kiemeney L.A.L.M., Witjes J.A., Prognosis of muscle-invasive bladder cancer: difference between primary and progressive Tumours and implications for therapy, Eur Urol, 45, pp. 292-296, (2004)

[6]

Gontero P., Birtle A., Comperat E., Dominguez J.L., Liedberg F., Mariappan P., Non-muscle-invasive Bladder Cancer (TaT1 and CIS) EAU Guidelines on 2024

[7]

Mengual L., Marin-Aguilera M., Ribal M.J., Et al., Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy, Eur Urol, 52, pp. 752-759, (2007)

[8]

Murakami K., Kamat A.M., Dai Y., Et al., Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: a pilot study, Cancer Biomark, 33, pp. 151-157, (2022)

[9]

Pierconti F., Martini M., Cenci T., Et al., The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma, Urol Oncol, 40, pp. 108.e19-108.e25, (2022)

[10]

Krajewski W., Rodriguez-Faba O., Breda A., Et al., The 1973 WHO and 2004 WHO grading systems are not equal in prediction of survival among stage T1 bladder cancer patients, Actas Urol Esp, 43, pp. 467-473, (2019)

← 1 2 3 →